(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Which Startup's Innovation Could Reform Medical care? - 2Vote In favor of Your Favored Kind Of Organic product
- 3Holyvolt And Wildcat Could Help The West Reclaim Battery Leadership
- 4Timothy Busfield turns himself in to face child sexual abuse charges in New Mexico
- 5Iran, Hezbollah fire rockets at Israel during Passover celebrations
- Manual for 6 famous sorts of cheddar
- Merz postpones Norway trip for Belgium talks on frozen Russian assets
- Well known Worldwide Caf\u00e9s to Experience
- An ex-FBI agent analyzes what we learned from Savannah Guthrie's 'Today' show interview amid the search for her mother Nancy
- Polls open in tense Uganda election amid widespread delays
- The most effective method to Succeed in Your Profession with a Web based Advertising Degree
- Eco-Accommodating Kitchen Machines: 4 Picks for a Manageable Home
- Avoid Slam: Clearing the Street for the Eventual fate of Standard Size Trucks
- 'The best gift ever': Baby is born after the rarest of pregnancies, defying all odds
